Development of Biomarker Signatures Associated with Anoikis to Predict Prognosis in Endometrial Carcinoma Patients

Figure 7

Analysis of immune checkpoints in EC. (a) PD1. (b) PD-L1. (c) PD-L2. (d) CTLA4. (e) TIM-3. (f) LAG3.

(a)

(b)

(c)

(d)

(e)

(f)